MCID: ADN009
MIFTS: 53

Adenosquamous Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 15 17 74
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 45
Carcinoma Adenosquamous 56

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 45 D018196
NCIt 51 C3727
SNOMED-CT 69 59367005
UMLS 74 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to pancreatic adenosquamous carcinoma and adenocarcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Development EGFR signaling pathway and Cytoskeletal Signaling. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and cervix, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 77 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
# Related Disease Score Top Affiliating Genes
1 pancreatic adenosquamous carcinoma 33.7 KRAS PTHLH
2 adenocarcinoma 31.0 EGFR KRAS MUC1 MUC4 TP53
3 adenoid squamous cell carcinoma 30.7 KRT7 KRT8
4 syringocystadenoma papilliferum 30.5 KRAS MUC1
5 hidradenoma 30.5 KRT7 MUC1
6 bile duct cystadenocarcinoma 30.5 KRT7 MUC1
7 gastrointestinal stromal tumor 30.5 EGFR KRAS TP53
8 in situ carcinoma 30.3 EGFR KRT5 TP53
9 cystadenocarcinoma 30.3 KRT7 MUC1 TP53
10 intestinal perforation 30.3 KRT7 NKX2-1
11 cystic teratoma 30.3 KRT7 NKX2-1 TP53
12 teratoma 30.3 KRT7 NKX2-1 TP53
13 lynch syndrome 30.3 EGFR KRAS TP53
14 large cell neuroendocrine carcinoma 30.2 EGFR KRT7 NKX2-1
15 carcinosarcoma 30.2 KRAS KRT7 MUC1 TP53
16 villous adenoma 30.1 KRAS KRT8 MUC1
17 mucoepidermoid carcinoma 30.1 EGFR KRT7 MUC1 MUC4 TP63
18 cystadenoma 30.1 KRT7 MUC1 MUC4
19 dermoid cyst 30.0 KRT7 MUC1 TP63
20 squamous cell carcinoma 30.0 EGFR MUC1 PTHLH TP53 TP63
21 spindle cell carcinoma 30.0 KRT5 KRT7 MUC1 TP63
22 small cell carcinoma 30.0 EGFR KRT7 NKX2-1 TP53
23 gastric squamous cell carcinoma 30.0 KRT5 KRT7 SERPINA3
24 small cell cancer of the lung 29.9 EGFR KRT7 NKX2-1 TP53
25 gallbladder cancer 29.9 EGFR KRAS MUC1 TP53
26 lymphoepithelioma-like carcinoma 29.9 KRT5 KRT7 KRT8 MUC1
27 necrotizing sialometaplasia 29.8 KRT5 KRT7 TP53 TP63
28 secretory meningioma 29.7 KRT7 MUC1
29 mucinous adenocarcinoma 29.6 EGFR KRAS KRT7 MUC1 NKX2-1
30 papilloma 29.4 KRT5 KRT7 KRT8 TP53 TP63
31 endometrial cancer 29.3 AR EGFR KRAS KRT7 TP53
32 lung cancer 28.5 EGFR KRAS KRT7 MUC4 NKX2-1 PTHLH
33 breast cancer 28.0 AR EGFR KRAS KRT5 KRT8 MUC1
34 endometrial adenosquamous carcinoma 12.5
35 glassy cell variant cervical adenosquamous carcinoma 12.4
36 gastric adenosquamous carcinoma 12.4
37 cervical adenosquamous carcinoma 12.4
38 esophageal adenosquamous carcinoma 12.4
39 thymus adenosquamous carcinoma 12.3
40 bartholin's gland adenosquamous carcinoma 12.2
41 ampulla of vater adenosquamous carcinoma 12.2
42 adenosquamous gallbladder carcinoma 11.7
43 adenosquamous colon carcinoma 11.7
44 adenosquamous prostate carcinoma 11.7
45 adenosquamous lung carcinoma 11.3
46 adenosquamous breast carcinoma 11.2
47 adenosquamous bile duct carcinoma 11.2
48 duodenum adenocarcinoma 10.5 KRAS KRT7
49 hepatoid adenocarcinoma 10.5 EGFR MUC1
50 anal canal adenocarcinoma 10.5 KRAS KRT7

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

27 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 KRT5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.77 KRT5 KRT8
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.77 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.77 KRT8
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 KRT7
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.77 KRT5 KRT7 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.77 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.77 KRT5 KRT7
10 Decreased viability GR00055-A-2 9.44 EGFR KRAS MUC1
11 Decreased viability GR00106-A-0 9.44 KRAS
12 Decreased viability GR00221-A-1 9.44 EGFR KRAS
13 Decreased viability GR00221-A-2 9.44 KRAS
14 Decreased viability GR00221-A-4 9.44 EGFR
15 Decreased viability GR00301-A 9.44 KRAS
16 Decreased viability GR00381-A-1 9.44 KRAS
17 Decreased viability GR00402-S-2 9.44 EGFR KRAS MUC1

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.18 AR EGFR KRAS KRT5 KRT8 NKX2-1
2 cardiovascular system MP:0005385 10.15 AR EGFR KRAS KRT8 NKX2-1 PTHLH
3 growth/size/body region MP:0005378 10.15 AR EGFR KRAS KRT5 KRT8 NKX2-1
4 craniofacial MP:0005382 10.08 AR EGFR KRAS KRT5 PTHLH TP53
5 endocrine/exocrine gland MP:0005379 10.05 AR EGFR KRAS NKX2-1 PTHLH TP53
6 integument MP:0010771 10.02 AR EGFR KRAS KRT5 PTHLH TP53
7 limbs/digits/tail MP:0005371 10 AR EGFR KRAS KRT5 PTHLH TP53
8 neoplasm MP:0002006 9.95 AR EGFR KRAS NKX2-1 PTHLH TP53
9 liver/biliary system MP:0005370 9.91 AR EGFR KRAS KRT8 PTHLH TP53
10 normal MP:0002873 9.87 AR EGFR KRAS NKX2-1 PTHLH TP53
11 no phenotypic analysis MP:0003012 9.85 EGFR KRAS KRT5 NKX2-1 TP53 TP63
12 renal/urinary system MP:0005367 9.8 AR EGFR KRAS KRT7 PTHLH TP53
13 reproductive system MP:0005389 9.76 AR EGFR KRAS KRT8 NKX2-1 PTHLH
14 respiratory system MP:0005388 9.43 EGFR KRAS NKX2-1 PTHLH TP53 TP63
15 skeleton MP:0005390 9.17 AR EGFR KRAS NKX2-1 PTHLH TP53

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
11
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
12
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
13
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
14
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
15
Ifosfamide Approved Phase 3 3778-73-2 3690
16
Vinblastine Approved Phase 3 865-21-4 241903 13342
17
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
18
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
19
Mecasermin Approved, Investigational Phase 3 68562-41-4
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
21
Doxil Approved June 1999 Phase 3,Phase 1 31703
22
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
26 Antimitotic Agents Phase 3,Phase 2,Phase 1
27 insulin Phase 3
28 Insulin, Globin Zinc Phase 3
29 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
30 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
31 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1
33 Immunoglobulin G Phase 3,Phase 2,Phase 1
34 Immunologic Factors Phase 3,Phase 2,Phase 1
35 Immunoglobulins Phase 3,Phase 2,Phase 1
36 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
37 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
38 Mitogens Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1
42 Antiviral Agents Phase 3,Phase 2,Phase 1
43 Antimetabolites Phase 3,Phase 2,Phase 1
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
45 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
47 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
49
Isophosphamide mustard Phase 3 0
50 Antirheumatic Agents Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
8 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
13 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
14 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
15 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
16 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
17 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
18 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
19 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
20 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
21 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
22 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
23 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
24 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
25 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
26 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
27 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
28 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
29 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
30 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
31 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01267253 Phase 2 Brivanib Alaninate
32 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
33 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
34 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
35 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
36 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
37 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
38 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
39 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
40 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCT00030485 Phase 2 erlotinib hydrochloride
41 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
42 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
43 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
44 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
45 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
46 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
47 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
48 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
49 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
50 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

42
Lung, Breast, Cervix, Pancreas, Colon, Prostate, Lymph Node

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 567)
# Title Authors Year
1
Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. ( 30516569 )
2019
2
Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases. ( 30258209 )
2019
3
Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. ( 30705898 )
2019
4
MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma. ( 30761272 )
2019
5
Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. ( 30788163 )
2019
6
Adenosquamous carcinoma of the uterine cervix displaying tumor-associated tissue eosinophilia. ( 30800306 )
2019
7
Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. ( 30828454 )
2019
8
A Rare Case of Adenosquamous Carcinoma Arising in a Background of IgG4-Related Lung Disease: A case report. ( 30853707 )
2019
9
Long-term outcomes after an aggressive resection of adenosquamous carcinoma of the pancreas. ( 30980180 )
2019
10
"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features: Erratum. ( 30985334 )
2019
11
Primary neoplasms of the uterus simultaneously presenting as neuroendocrine carcinoma of the cervix and adenosquamous carcinoma of the endometrium: a case report. ( 31023120 )
2019
12
Malignant adenomyoepithelioma with multifocal adenosquamous carcinoma of the breast: A case report. ( 31062450 )
2019
13
Endoscopic Findings of Esophageal Adenosquamous Carcinoma Diagnosed by Endoscopic Mucosal Resection. ( 31097930 )
2019
14
Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability. ( 30173239 )
2018
15
A retroperitoneal mass confirmed as a pancreatic adenosquamous carcinoma by endoscopic ultrasound-guided fine-needle aspiration. ( 29069702 )
2018
16
Adenosquamous Carcinoma of the Tongue. ( 29243024 )
2018
17
Spontaneous pulmonary adenosquamous carcinoma in a free-living black capuchin monkey (Sapajus nigritus). ( 29283438 )
2018
18
Clinicopathological characteristics and survival outcomes in adenosquamous carcinoma of the lung: a population-based study from the SEER database. ( 29487721 )
2018
19
High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. ( 29537649 )
2018
20
Adenosquamous carcinoma of the bile duct: a population-based study. ( 29563834 )
2018
21
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. ( 29609906 )
2018
22
Long-term survival with extended lateral lymphadenectomy for lateral lymph node recurrence after laparoscopic abdominoperineal resection for rectal adenosquamous carcinoma: a case report. ( 29633041 )
2018
23
Pancreatic adenosquamous carcinoma masquerading as a locally invading splenic abscess. ( 29740918 )
2018
24
A Rare Case of Penile Metastases as a Harbinger of Primary Pulmonary Adenosquamous Carcinoma. ( 29785317 )
2018
25
Adenosquamous Carcinoma in the Midline Dorsum of the Tongue: A Rare Case Report. ( 29806990 )
2018
26
Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes. ( 29850145 )
2018
27
Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. ( 29878370 )
2018
28
Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. ( 29983579 )
2018
29
Adenosquamous Carcinoma of the Esophagus: A Literature Review. ( 29984200 )
2018
30
Adenosquamous Carcinoma of the Ampulla of Vater: A Rare Cause of Obstructive Jaundice. ( 29998166 )
2018
31
Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. ( 30040455 )
2018
32
Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. ( 30100056 )
2018
33
Adenosquamous carcinoma of the right colon: A case report and review of the literature. ( 30103094 )
2018
34
Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. ( 30122989 )
2018
35
"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features. ( 30138216 )
2018
36
Adenosquamous carcinoma of the lung. ( 30147334 )
2018
37
Adenosquamous carcinoma arising in a duplication cyst of the gallbladder. ( 30221164 )
2018
38
Survival analysis for lung adenosquamous carcinoma patients with brain metastasis. ( 30405840 )
2018
39
Research progress of the clinicopathologic features of lung adenosquamous carcinoma. ( 30410358 )
2018
40
Adenosquamous carcinoma of the papilla of Vater: A phenotypic heterogeneity characterized by a common molecular landscape. ( 30417956 )
2018
41
Low-grade Adenosquamous Carcinoma of the Breast: A Case Report. ( 30449342 )
2018
42
Adenosquamous Carcinoma of the Anus: An Uncommon Malignancy Presenting a Treatment Challenge. ( 30454337 )
2018
43
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. ( 30477643 )
2018
44
Atypical presentation of adenosquamous carcinoma: A case report. ( 30574311 )
2018
45
Adenosquamous Carcinoma of the Choledochus. ( 30686962 )
2018
46
[The efficacy and influence factors analysis of EGFR TKIs on patients with lung adenosquamous carcinoma]. ( 30392343 )
2018
47
Adenosquamous carcinoma of the tongue: clinicopathologic study and review of the literature. ( 27456683 )
2017
48
Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. ( 27646608 )
2017
49
The Squamous Cells of Adenosquamous Carcinoma (ASCC) of the Prostate Might Represent a Terminally Differentiated Quiescent Component: Immunohistochemical Evidence From a Case of ASCC With Pleomorphic Giant Tumor Cells. ( 27753662 )
2017
50
Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. ( 28028992 )
2017

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.7 AR EGFR KRT5 KRT7 KRT8 MUC1
2 keratin filament GO:0045095 9.33 KRT5 KRT7 KRT8
3 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.84 AR KRAS NKX2-1 TP53
2 cell proliferation GO:0008283 9.81 AR EGFR TP53 TP63
3 positive regulation of transcription, DNA-templated GO:0045893 9.72 AR EGFR NKX2-1 TP53 TP63
4 cornification GO:0070268 9.63 KRT5 KRT7 KRT8
5 anatomical structure formation involved in morphogenesis GO:0048646 9.55 NKX2-1 TP63
6 epithelial tube branching involved in lung morphogenesis GO:0060441 9.52 KRAS NKX2-1
7 prostate gland development GO:0030850 9.49 AR TP63
8 maintenance of gastrointestinal epithelium GO:0030277 9.48 MUC4 SERPINA3
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 MUC1 TP53
10 cerebral cortex cell migration GO:0021795 9.4 EGFR NKX2-1
11 Leydig cell differentiation GO:0033327 9.37 AR NKX2-1
12 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 KRAS MUC1 MUC4
13 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.26 EGFR TP53
14 morphogenesis of an epithelial fold GO:0060571 8.96 AR EGFR
15 epidermis development GO:0008544 8.92 EGFR KRT5 PTHLH TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.62 AR MUC1 NKX2-1 TP53
2 chromatin binding GO:0003682 9.56 AR EGFR TP53 TP63
3 enzyme binding GO:0019899 9.46 AR EGFR NKX2-1 TP53
4 transcription regulatory region DNA binding GO:0044212 9.26 AR NKX2-1 TP53 TP63
5 p53 binding GO:0002039 8.8 MUC1 TP53 TP63

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....